Jun 18 |
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease
|
May 29 |
Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
|
May 15 |
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
|
May 9 |
Spyre Therapeutics GAAP EPS of -$1.20
|
May 9 |
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
Apr 19 |
Spyre Therapeutics files to sell 33.36M shares of common stock for holders
|
Mar 18 |
Spyre Therapeutics climbs 5%, prices $180M private financing
|
Feb 29 |
Spyre Therapeutics GAAP EPS of -$4.05
|
Feb 29 |
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
Feb 26 |
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
|